文献速递类风湿关节炎血管炎其他结缔组织病

重组带状疱疹疫苗在风湿病患者中的安全性:622例回顾性研究

Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该单中心回顾性研究纳入622例接受重组带状疱疹疫苗(RZV)的风湿科患者,其中359例为免疫介导炎症性疾病(IMID)患者。结果显示RZV总体耐受良好,但IMID患者接种后12周内轻度复发并不少见,接种时使用糖皮质激素与复发风险增加相关。

要点

  • RZV在风湿病患者中总体耐受良好,8.5%出现不良事件,带状疱疹发生率0.6%。
  • IMID患者接种后复发率16%,类风湿关节炎患者复发率最高(24%)。
  • 接种时使用糖皮质激素与复发风险增加独立相关(OR 2.31)。

核心结论

  • RZV在IMID患者中总体耐受良好,但接种后12周内轻度复发并不少见。
  • 接种时使用糖皮质激素是IMID复发的显著预测因素。
  • 首次接种后复发与第二次接种后复发相关。

研究设计与样本

  • 单中心风湿科回顾性研究,纳入接受RZV的患者622例,其中IMID患者359例。
  • IMID复发定义为接种每剂后12周内病历记录复发或新开泼尼松处方。

主要发现

  • 622例患者中67%为女性,中位年龄67岁,8.5%经历不良事件,中位随访36周后带状疱疹发生率为0.6%。
  • 359例IMID患者中,88例为类风湿关节炎(25%),50例为血管炎(14%),29例为风湿性多肌痛(8%)。
  • 接种时35%使用糖皮质激素;59例(16%)经历复发,其中18例复发与治疗调整有时间关联(31%)。
  • 类风湿关节炎患者复发率最高(n=21,24%),复发患者中25%需要调整免疫抑制治疗。
  • 多变量分析显示接种时使用糖皮质激素与接种后复发相关[OR 2.31(1.3-4.1),P=0.004]。

关键数值与推荐

  • Cox模型显示糖皮质激素是首次RZV接种后IMID复发的显著预测因素[HR 2.4(1.3-4.5),P=0.0039]。
  • 首次接种后复发与第二次RZV接种后复发相关[HR 3.9(1.7-9),P=0.0015]。

临床怎么用

  • RZV可用于IMID患者,但应告知接种后12周内轻度复发风险,尤其在使用糖皮质激素者。
  • 对接种时使用糖皮质激素的患者,应加强复发监测。
  • 首次接种后出现复发的患者,再次接种前需评估复发风险。

局限性

  • 单中心回顾性设计,可能存在选择偏倚和记录不完整。
  • 复发定义依赖病历记录或新开泼尼松处方,可能遗漏未记录事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To provide insight into the safety of recombinant zoster vaccine (RZV) in patients with immune-mediated inflammatory diseases (IMID). METHODS: Patients who received RZV in a single-centre rheumatology department were retrospectively included. An IMID flare was defined as (i) a documentation of flare in the office notes or patient portal communication or (ii) new prednisone prescription, in the 12 weeks after each dose. RESULTS: Six-hundred and twenty-two patients were included (67% female, median age 67 years), 8.5% of them experienced adverse events (AEs) and herpes zoster (HZ) incidence was 0.6% after median follow-up of 36 weeks. Of 359 IMID patients: 88 had RA (25%), 50 vasculitis (14%) and 29 PMR (8%). At vaccination, 35% were on glucocorticoids (GC). Fifty-nine patients (16%) experienced a flare, 18 flares occurred in temporal relation to a treatment change (31%). RA patients had the highest flare rate (n = 21, 24%), 25% of patients who flared required adjustment of immunosuppression. In a multivariate analysis, use of GC at time of vaccination was associated with flare after vaccination [odds ratio (OR) 2.31 (1.3-4.1), P =0.004]. A time-to-flare survival analysis (Cox-model) showed that GC was a significant predictor of IMID flare after first RZV dose [hazard ratio (HR) 2.4 (1.3-4.5), P =0.0039] and that a flare after the first dose was associated with flaring after the second RZV dose [HR 3.9 (1.7-9), P =0.0015]. CONCLUSION: RZV administration in patients with IMIDs was generally well-tolerated, though mild flares were not uncommon in the first 12 weeks after vaccination. These data may provide useful information for patient education when considering RZV administration.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021. PMID: 33560302. doi:10.1093/rheumatology/keab139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。